[
  {
    "ts": "2026-02-14T03:02:08+00:00",
    "headline": "InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit",
    "summary": "InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit 2026. Chief Financial Officer Thomas Taapken and investor relations executive Jan Medina also discus",
    "url": "https://www.marketbeat.com/instant-alerts/inflarx-spotlights-izicopan-hs-data-phase-2b-plans-and-30-cost-cuts-at-guggenheim-summit-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "57014b06-c5cd-343b-8333-4138331bf576",
      "content": {
        "id": "57014b06-c5cd-343b-8333-4138331bf576",
        "contentType": "STORY",
        "title": "InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit",
        "description": "",
        "summary": "InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit 2026. Chief Financial Officer Thomas Taapken and investor relations executive Jan Medina also discus",
        "pubDate": "2026-02-14T03:02:08Z",
        "displayTime": "2026-02-14T03:02:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/954763c2de68b7af48079a72a53c2032",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "InflaRx logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sd5hRYNKQucT6nau9sb_AA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/954763c2de68b7af48079a72a53c2032.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/USgFecapiNFjGPxmx3DeIA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/954763c2de68b7af48079a72a53c2032.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/inflarx-spotlights-izicopan-hs-data-phase-2b-plans-and-30-cost-cuts-at-guggenheim-summit-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/inflarx-spotlights-izicopan-hs-data-030208951.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IFRX"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-14T06:09:55+00:00",
    "headline": "Is UPLIZNA’s EU Approval Reframing Amgen’s Rare Disease Strategy And Investment Case (AMGN)?",
    "summary": "Amgen recently reported past fourth-quarter and full-year 2025 results showing higher revenues of US$9.87 billion for the quarter and US$36.75 billion for the year, alongside increased net income and earnings per share. Shortly after those results, the European Commission approved UPLIZNA as an add-on therapy for certain adults with generalized myasthenia gravis, extending Amgen’s reach in rare autoimmune diseases with an infusible, twice-yearly maintenance option. We’ll now examine how the...",
    "url": "https://finance.yahoo.com/news/uplizna-eu-approval-reframing-amgen-060955041.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5175db0c-c417-370d-8ddf-051759cacb85",
      "content": {
        "id": "5175db0c-c417-370d-8ddf-051759cacb85",
        "contentType": "STORY",
        "title": "Is UPLIZNA’s EU Approval Reframing Amgen’s Rare Disease Strategy And Investment Case (AMGN)?",
        "description": "",
        "summary": "Amgen recently reported past fourth-quarter and full-year 2025 results showing higher revenues of US$9.87 billion for the quarter and US$36.75 billion for the year, alongside increased net income and earnings per share. Shortly after those results, the European Commission approved UPLIZNA as an add-on therapy for certain adults with generalized myasthenia gravis, extending Amgen’s reach in rare autoimmune diseases with an infusible, twice-yearly maintenance option. We’ll now examine how the...",
        "pubDate": "2026-02-14T06:09:55Z",
        "displayTime": "2026-02-14T06:09:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/uplizna-eu-approval-reframing-amgen-060955041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/uplizna-eu-approval-reframing-amgen-060955041.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]